You have 9 free searches left this month | for more free features.

Condition

Acute Myeloid Leukemia (AML) (2)

High-risk Myelodysplastic Syndrome (MDS) (1)

Multiple Myeloma (MM) (1)

Myelofibrosis (1)

Non-Hodgkin Lymphoma (NHL) (1)

PMF (1)

Post-Essential Thrombocythemia Myelofibrosis (1)

Post-Polycythemia Vera Myelofibrosis (1)

Primary Myelofibrosis (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 1 (3)

Sponsor

Novartis Pharmaceuticals (3)

Collaborator

Intervention

mbg453 (2)

decitabine (1)

hdm201 (1)

mik665 (1)

nis793 (1)

spartalizumab (1)

venetoclax (1)

vob560 (1)

Study Documents

Intervention Type

drug (3)

biological (1)

Funder Type

Industry (3)

Study Type

Interventional (3)

BHLRM

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting

Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)

HDM201
+2 more

Durham, North Carolina
+8 more

Dec 13, 2022

Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial in Worldwide (VOB560, MIK665)

Recruiting

Non-Hodgkin Lymphoma (NHL)
+2 more

Gent, Belgium
+9 more

Mar 18, 2022

Primary Myelofibrosis, Myelofibrosis, PMF Trial (MBG453, NIS793, Spartalizumab)

Withdrawn

Primary Myelofibrosis
+4 more

MBG453
+3 more

(no location specified)

Mar 2, 2021